Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

"xn-person">Andrew R. Haas, M.D., Ph.D., Hospital of the University of Pennsylvania, and investigator on JX-594 Phase 1 trial.

This open-label, dose-escalation study was completed at four sites in the United States and Canada.  A total of 23 patients with solid tumors refractory to standard therapy were enrolled.  Patients received a single treatment at one of five dose levels, with follow-up at periodic intervals.  Six out of eight patients in the higher-dose cohorts evaluable to date (cohorts 3, 4, 5) exhibited disease control as defined by stable disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria and/or Choi (necrotic) response.  Two out of six patients in the low dose cohorts exhibited disease control (RECIST stable disease) but no responses.  The primary endpoints of the trial included safety and determination of the maximum tolerated dose given through intravenous administration.  No serious adverse events related to JX-594 therapy were reported and no dose-limiting toxicities were reported.  A biomarker analysis further strengthened the finding of dose-dependent replication in tumors following IV administration.

About JX-594

JX-594, currently in Phase 2 clinical trials for liver cancer, is a cancer biotherapeutic product from a proprietary breakthrough class of targeted and armed oncolytic and immunotherapeutic poxviruses.  Tumor destruction and safety was shown in patients with diverse cancer types in three Phase 1 trials; treated patients were end-stage and had no effective therapies available.  JX-594 multiplies selectively within cancer cells, leading to their destruction.  These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... Europe and the United States and plenary talks by ... for SPIE Optics + Optoelectronics next month ... 700 technical presentations in 17 conferences alongside a two-day ... optics and photonics , the event will run 13-16 ...
(Date:3/30/2015)... Wis. , March 30, 2015  FUJIFILM Holdings ... and Cellular Dynamics International, Inc. (CEO: Robert J. ... developer and manufacturer of fully functioning human cells in ... two companies have entered into a definitive agreement whereby ... to be followed by a second step merger. Fujifilm ...
(Date:3/29/2015)... As a symbol of its commitment to ... manufacturing clients, Whitehouse Laboratories is excited to announce that ... Team for the 2015 race season. Success on the ... strong sense of precision and attention to detail. These ... the quality control testing laboratory. Sponsorship of the race ...
(Date:3/27/2015)...  Neogen Corporation (NASDAQ: NEOG ) announced today ... plan in accordance with Securities and Exchange Commission rule ... Neogen Corporation, is a minority owner of this entity ... Herbert does not have control of this entity, ... only for a portion of the shares owned by ...
Breaking Biology Technology:Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2Neogen CEO adopts 10b5-1 Trading Plan 2
... CHARLOTTESVILLE, Va., Dec. 21 Diffusion Pharmaceuticals,LLC, ... utilizing a novel mechanism of action that ... its key advisors, Mr. Thomas,Byrne, was recently ... of Amgen,s blockbuster drug Aranesp(R) (darbepoietin alpha), ...
... to serve Pacific Northwest, SEATTLE, Dec. 21 ... the western Washington state congressional delegation has,resulted in ... development,of a state-of-the-art proton-beam therapy center by the ... in the 2008 Omnibus Appropriations,bill signed by President ...
... 21 Abbott (NYSE: ABT ),will present at ... 7, 2008. Thomas C. Freyman, executive vice president, finance ... the company at,11:00 a.m. Central time., A live ... Investor Relations Web site at http://www.abbottinvestor.com . An,archived ...
Cached Biology Technology:Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics 2Murray Leads Delegation in Securing $2.1 Million for Proton Therapy Center 2Murray Leads Delegation in Securing $2.1 Million for Proton Therapy Center 3
(Date:3/11/2015)... --  The Sync Project™ today announced the ... harness music to improve health. The platform maps ... of physiology, enabling the study of the therapeutic ... It is designed for medical and health research, ... and accelerate the discovery of the clinical applications ...
(Date:3/10/2015)... 10, 2015   Tute Genomics , pioneer in ... by next-generation sequencing company PrimBio Research Institute ... targeted gene panel interpretation. PrimBio, a certified ... most current technologies to support the work of experts ... offers two types of exome sequencing services: 1) Targeted ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3
... Athens, Ga. Most convenience stores have a wide variety ... While shoppers can buy calorie-heavy foods wrapped in pretty packages ... fresh produce, whole grains and low-fat dairy products necessary for ... nearby food source for millions of Americans living in what ...
... Calif.) Magnetic resonance imaging (MRI) on the nanoscale and ... toward the realm of possibility, and a new study co-authored ... extra nudge. The findings appear today in Science ... Ania Bleszynski Jayich, an assistant professor of physics who ...
... in their brain cells a survival secret that might lead ... Illinois at Chicago biologist Thomas Park and colleagues at UIC ... Antonio think the subterranean lifestyle of the pasty-looking rodents may ... when oxygen is scarce. The key may lie in how ...
Cached Biology News:Healthy foods missing from stores in low-income black neighborhoods, UGA study finds 2Healthy foods missing from stores in low-income black neighborhoods, UGA study finds 3Healthy foods missing from stores in low-income black neighborhoods, UGA study finds 4UC Santa Barbara researcher's new study may lead to MRIs on a nanoscale 2Naked mole-rats bear lifesaving clues 2